FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								

0.5

hours per response:

Check this box if no longer subject	τo
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(h)	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					01 5	ection	1 30(11)	or the	mvesime	ent Co	прапу Аст	01 194	+0								
1. Name and Address of Reporting Person* MCLAIN THOMAS H						2. Issuer Name and Ticker or Trading Symbol NABI BIOPHARMACEUTICALS [NABI]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
MCLAI	IN THUI	MAS II												1	X Director 10% Own					wner	
(Last)	(Fi	rst) (Middle)			Date of Earliest Transaction (Month/Day/Year)								\dashv	A b	elow	,		below)		
C/O NABI BIOPHARMACEUTICALS					11/3	11/30/2004										Cha	hairman, CEO & President				
5800 PAF	RK OF CO	MMERCE BLVI	D., N.W.											4							
(Street)	ATON FI	. 3	33487	4. If Amendment, Date of Original Filed (Month/Day/Yea							ar)		ine) <mark>X</mark> F	orm	al or Joint/Group Filing (Check Applicable orm filed by One Reporting Person						
(City)	(SI	rate) (Zip)													orm	filed by Mor on	re thai	n One Rep	orting	
		Tabl	e I - No	n-Deriv	ative	Sec	uritie	s Ac	quired	, Dis	sposed o	f, oı	Ben	efici	ally Ov	vne	d				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (/ Disposed Of (D) (Instr. 3				d 5) Se Be Ov	curit enefic vned	mount of curities neficially ned Following		wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount		(A) or (D)	Price			action(s) 3 and 4)			(Instr. 4)		
Common	Stock			11/30/	2004				J ⁽¹⁾	V	1,056.91	.06	A	\$1	2.3 4	1 7,5	47.8114		D		
Common	Stock															2	.40 ⁽²⁾	I By childre			
		Та									osed of, onvertib				y Own	ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transaction Code (Instr. B)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date I Expirati (Month/I	on Da		or		str. 3 ount	8. Price of Derivative Security (Instr. 5)	ve /	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						V	(A)	(D)	Exercisa	able	Date	Title		res							

Explanation of Responses:

- 1. Voluntarily reported acquisition under the issuer's 2000 Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3(c).
- 2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

/s/ James E. Dawson, as 12/20/2004 attorney-in-fact ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.